KPTI Karyopharm Therapeutics - to submit snda to FDA in August 2026 for selinexor plus ruxolitinib in myelofibrosis
KPTI Karyopharm Therapeutics - to submit snda to FDA in August 2026 for selinexor plus ruxolitinib in myelofibrosis
Story updates
08:29:00 PM UTC
SquawkNews
KPTI Karyopharm plans to submit snda for selinexor plus ruxolitinib in myelofibrosis under accelerated approval pathway
08:29:22 PM UTC
SquawkNews
KPTI Karyopharm Therapeutics - to submit snda to FDA in August 2026 for selinexor plus ruxolitinib in myelofibrosis
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.